CJC-1295 Source Numbers Lead Back to the Papers
Blood hormone tests in people and growth studies in animals answer different questions. The CJC-1295 list includes stage 1 early safety work and drug-agency papers. Source numbers lead to the supporting papers.
Each Source Shows Who Was Studied and What Was Found
Human tests measured hormones; animal tests measured changes in growth. CJC-1295 has two published stage 1 studies of early human safety. The stage 2 trial of possible benefit stopped before finishing. Animal studies and drug-agency papers answer other questions about the substance. Numbers beside the findings match the source numbers listed below. A number beside a figure identifies the supporting paper.
Your source link shows what evidence lies behind the finding.
Links lead to papers or medical study listings where available. The table can sort papers by year, journal, or source kind. A journal is a magazine publishing medical or scientific papers. Sorting by journal groups papers by where they were published. Author names and paper details stay as published. Source kind matters more than magazine name. Animal research can't prove a health benefit for people.
- Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
- Coy DH, et al. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. Journal of Clinical Endocrinology and Metabolism. 1994. ↗
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. ↗
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. ↗
- aidsmap editorial team. Lipodystrophy study halted after patient death (news report on ConjuChem CJC-1295 Phase 2 trial NCT00267527). aidsmap (NAM Publications). 2006. ↗
- FDA. Safety-risk page current as of April 22, 2026: withdrawn nominations for CJC-1295 and ipamorelin acetate under 503A, the patient-specific pharmacy policy, with the FDA safety concerns retained. FDA Federal Register / Docket FDA-2024-N-4777. 2024. ↗
- World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA Prohibited List. 2024. ↗
- Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism. 2006;291(6):E1290-E1294. ↗
- ConjuChem Biotechnologies. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527). ClinicalTrials.gov. 2005. ↗
- Wikipedia editors (citing primary literature on D-Ala2 substitution kinetics). Modified GRF (1-29) - chemical and pharmacological description. 2024. ↗
- Bagno LL, Kanashiro-Takeuchi RM, Suncion VY, et al. Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. Journal of the American Heart Association. 2015. ↗
- Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. ↗
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 (route-of-administration record). Journal of Clinical Endocrinology and Metabolism. 2006. ↗
- ConjuChem Biotechnologies (legacy product documentation, summarized in regulatory filings). Modified GRF (1-29) and CJC-1295 handling — research-use product literature. FDA Docket FDA-2024-N-4777-0002 attachment 7. 2024. ↗
- Vijayakumar A, et al. The fascinating interplay between growth hormone, insulin-like growth factor-1, and insulin. Endocrinology and Metabolism (Korea). 2024. ↗
- FDA. CJC-1295 and ipamorelin acetate: withdrawn 503A nominations; ipamorelin acetate also retains a Category 2 entry under the 503B outsourcing-facility policy. FDA Federal Register / Docket FDA-2024-N-4777. 2024. ↗
- Traynor K. FDA approves tesamorelin for HIV-related lipodystrophy. American Journal of Health-System Pharmacy. 2010;67(24):2082. ↗
- Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2010;2(11-12). ↗
- Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis. 2021. ↗
- Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H, Klibanski A. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Annals of Internal Medicine. 1996. ↗